- Home
- CAC vs PLRX Comparison
CAC vs PLRX Comparison
Compare CAC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- PLRX
- Stock Information
- Founded
- CAC 1875
- PLRX 2015
- Country
- CAC United States
- PLRX United States
- Employees
- CAC N/A
- PLRX N/A
- Industry
- CAC Major Banks
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- PLRX Health Care
- Exchange
- CAC Nasdaq
- PLRX Nasdaq
- Market Cap
- CAC 680.5M
- PLRX 93.3M
- IPO Year
- CAC 1997
- PLRX 2020
- Fundamental
- Price
- CAC $38.15
- PLRX $1.68
- Analyst Decision
- CAC Buy
- PLRX Hold
- Analyst Count
- CAC 3
- PLRX 11
- Target Price
- CAC $47.33
- PLRX $3.93
- AVG Volume (30 Days)
- CAC 84.0K
- PLRX 1.0M
- Earning Date
- CAC 10-28-2025
- PLRX 11-07-2025
- Dividend Yield
- CAC 4.40%
- PLRX N/A
- EPS Growth
- CAC 9.12
- PLRX N/A
- EPS
- CAC 3.49
- PLRX N/A
- Revenue
- CAC $215,172,000.00
- PLRX N/A
- Revenue This Year
- CAC $42.11
- PLRX N/A
- Revenue Next Year
- CAC $5.51
- PLRX N/A
- P/E Ratio
- CAC $10.92
- PLRX N/A
- Revenue Growth
- CAC 27.50
- PLRX N/A
- 52 Week Low
- CAC $34.53
- PLRX $1.10
- 52 Week High
- CAC $50.07
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- CAC 51.09
- PLRX 52.58
- Support Level
- CAC $37.01
- PLRX $1.72
- Resistance Level
- CAC $39.89
- PLRX $1.95
- Average True Range (ATR)
- CAC 1.20
- PLRX 0.13
- MACD
- CAC 0.28
- PLRX 0.00
- Stochastic Oscillator
- CAC 64.45
- PLRX 43.75
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.